A Novel 9-Day Desensitization Protocol for Elexacaftor/Tezacaftor/Ivacaftor in a Child with Cystic Fibrosis

World Allergy Organization Journal 2026 Open access

Read full text
Authors: Rana Hassanin, Zahra Mohamed Hassan, Ghalib Al-Mawali, Tariq Al Farsi
DOI: 10.1016/j.waojou.2026.101265
Cited by: 0

Abstract

Despite the revolutionary role of Trikafta in the management of cystic fibrosis in children, hypersensitivity has been recognised. Herein, we present a case of hypersensitivity reaction to elexacaftor/tezacaftor/ivacaftor (Trikafta) in an early adolescent male with cystic fibrosis. The patient developed a diffuse maculopapular rash and shortness of breath 8 days after initiating therapy, necessitating treatment cessation. 10 days later caused the maculopapular rash to recur after two doses, thus confirming hypersensitivity.

Fields of Study & Subjects

Drug-Induced Adverse Reactions Pharmacovigilance and Adverse Drug Reactions Cystic Fibrosis Research Advances

Publication details

Journal / source
World Allergy Organization Journal
Volume
19
Issue
2
Pages
101265–101265
Publication date
1 February 2026
Language
EN